Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
|Videos|December 18, 2020
Blueprint
Author(s)Danny Freed
The CEO and founder of Blueprint talks how they are improving the quality of mental health care by putting the proper data infrastructure in place.
Advertisement
Blueprint's goal is more efficient and effective mental health care. How are they doing it? Listen as their CEO and founder, Danny Freed, talks more.
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5